Compare MNDO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNDO | BOLD |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 28.4M |
| IPO Year | 2000 | 2024 |
| Metric | MNDO | BOLD |
|---|---|---|
| Price | $1.16 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 26.1K | ★ 178.1K |
| Earning Date | 03-03-2026 | 03-26-2026 |
| Dividend Yield | ★ 19.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $19,770,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $0.96 |
| 52 Week High | $2.13 | $2.48 |
| Indicator | MNDO | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 41.72 |
| Support Level | $1.19 | $0.96 |
| Resistance Level | $1.25 | $1.20 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.09 | 46.87 |
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.